La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Poly Medicure Résultats passés
Passé contrôle des critères 5/6
Poly Medicure a connu une croissance annuelle moyenne de ses bénéfices de 23.1%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en hausse à 16% par an. Les revenus ont augmenté de en hausse à un taux moyen de 16.8% par an. Le rendement des capitaux propres de Poly Medicure est 18.3% et ses marges nettes sont de 18.7%.
Informations clés
23.1%
Taux de croissance des bénéfices
21.1%
Taux de croissance du BPA
| Medical Equipment Croissance de l'industrie | 23.0% |
| Taux de croissance des recettes | 16.8% |
| Rendement des fonds propres | 18.3% |
| Marge nette | 18.7% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being
Sep 20
Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00
Sep 14After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar
Sep 06Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet
Aug 14Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138
Jul 27Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)
Jul 11Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations
May 25Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital
May 12Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up
Mar 23Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today
Feb 15Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly
Jan 16Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?
Nov 14Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward
Oct 24Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being
Sep 22Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00
Sep 08Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly
Aug 12Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching
Jul 13Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return
Jun 16Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital
Mar 02We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Feb 14Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal
Oct 16We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt
Sep 28Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50
Sep 08Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly
Jun 25A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)
Jun 07Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends
May 23With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting
Feb 23There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital
Feb 04Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly
Jan 12With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting
Oct 14Poly Medicure (NSE:POLYMED) Could Easily Take On More Debt
Jul 07Poly Medicure (NSE:POLYMED) Will Will Want To Turn Around Its Return Trends
Jun 18Poly Medicure's (NSE:POLYMED) Solid Profits Have Weak Fundamentals
May 31Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹1,195
May 26Shareholders of Poly Medicure (NSE:POLYMED) Must Be Delighted With Their 448% Total Return
Mar 01I Ran A Stock Scan For Earnings Growth And Poly Medicure (NSE:POLYMED) Passed With Ease
Feb 16Ventilation des recettes et des dépenses
Comment Poly Medicure gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 14,397 | 2,696 | 2,590 | 188 |
| 31 Mar 24 | 13,758 | 2,583 | 2,516 | 190 |
| 31 Dec 23 | 13,046 | 2,487 | 2,349 | 198 |
| 30 Sep 23 | 12,498 | 2,337 | 2,278 | 193 |
| 30 Jun 23 | 11,872 | 2,150 | 2,151 | 182 |
| 31 Mar 23 | 11,152 | 1,793 | 2,076 | 178 |
| 31 Dec 22 | 10,659 | 1,566 | 1,979 | 171 |
| 30 Sep 22 | 10,113 | 1,411 | 1,866 | 178 |
| 30 Jun 22 | 9,600 | 1,359 | 1,751 | 188 |
| 31 Mar 22 | 9,231 | 1,465 | 1,671 | 188 |
| 31 Dec 21 | 8,785 | 1,492 | 1,590 | 174 |
| 30 Sep 21 | 8,518 | 1,500 | 1,544 | 159 |
| 30 Jun 21 | 8,280 | 1,468 | 1,489 | 140 |
| 31 Mar 21 | 7,865 | 1,359 | 1,448 | 131 |
| 31 Dec 20 | 7,448 | 1,197 | 1,434 | 129 |
| 30 Sep 20 | 7,218 | 1,094 | 1,409 | 124 |
| 30 Jun 20 | 6,960 | 1,028 | 1,359 | 121 |
| 31 Mar 20 | 6,872 | 959 | 1,431 | 119 |
| 31 Dec 19 | 6,881 | 947 | 1,427 | 97 |
| 30 Sep 19 | 6,625 | 858 | 1,377 | 98 |
| 30 Jun 19 | 6,388 | 719 | 1,229 | 100 |
| 31 Mar 19 | 6,108 | 654 | 1,224 | 101 |
| 31 Mar 18 | 5,204 | 706 | 1,035 | 100 |
| 31 Mar 17 | 4,550 | 551 | 931 | 90 |
| 31 Mar 16 | 4,123 | 483 | 791 | 87 |
| 31 Mar 15 | 3,903 | 623 | 687 | 85 |
| 31 Mar 14 | 3,222 | 451 | 784 | 59 |
Des revenus de qualité: POLYMED a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de POLYMED (18.7%) sont supérieures à celles de l'année dernière (18.1%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de POLYMED ont augmenté de manière significative de 23.1% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de POLYMED au cours de l'année écoulée ( 25.4% ) dépasse sa moyenne sur 5 ans ( 23.1% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices POLYMED au cours de l'année écoulée ( 25.4% ) a dépassé celle du secteur Medical Equipment 11.9%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de POLYMED ( 18.3% ) est considéré comme faible.